Insmed (NASDAQ:INSM) Sees Strong Trading Volume – Should You Buy?

Insmed, Inc. (NASDAQ:INSM – Get Free Report) shares saw unusually-strong trading volume on Thursday. Approximately 3,398,887 shares changed hands during trading, an increase of 14% from the average daily volume of 2,982,692 shares. The stock last traded at $136.6630 and had previously closed at $119.80.

Insmed News Summary

Here’s some of the latest news about INSM:

  • Positive Sentiment: Reports that Sanofi is exploring a potential acquisition drove a strong rally in Insmed shares. One analyst cited in coverage suggested a takeover could value the stock at $170–$210 per share, although no deal has been announced. Insmed shares jump as Sanofi weighs potential takeover
  • Neutral Sentiment: An Insmed insider sold 101,100 shares, reducing her stake by about 71%. The transaction was made under a pre-arranged Rule 10b5-1 plan, which may temper concerns that the sale reflects a reaction to recent developments.
  • Negative Sentiment: The takeover reports are speculative, and analysts are divided over whether a deal would bring pipeline benefits or create financial strain. The lack of a confirmed offer may contribute to caution and profit-taking after the previous session’s surge. Analysts split on potential Sanofi-Insmed deal

Analyst Ratings Changes

INSM has been the topic of several analyst reports. Weiss Ratings lowered shares of Insmed from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday. Truist Financial reaffirmed a “buy” rating and issued a $195.00 price objective (up from $185.00) on shares of Insmed in a research note on Monday, August 10th. Raymond James Financial set a $173.00 target price on shares of Insmed in a report on Tuesday, October 20th. BMO Capital Markets reaffirmed an “outperform” rating on shares of Insmed in a report on Tuesday, October 6th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $175.00 target price on shares of Insmed in a research report on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $196.52.

Check Out Our Latest Research Report on Insmed

Insmed Stock Performance

The company has a quick ratio of 2.59, a current ratio of 2.86 and a debt-to-equity ratio of 0.77. The stock has a market cap of $31.00 billion, a P/E ratio of -50.12 and a beta of 0.83. The stock has a fifty day simple moving average of $111.09 and a 200-day simple moving average of $122.71.

Insmed (NASDAQ:INSM – Get Free Report) last posted its earnings results on Thursday, October 29th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.08). The company had revenue of $524.43 million for the quarter, compared to analyst estimates of $500.36 million. Insmed had a negative return on equity of 96.38% and a negative net margin of 39.85%. Insmed’s quarterly revenue was up 268.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($1.75) earnings per share. Equities analysts expect that Insmed, Inc. will post -1.86 earnings per share for the current fiscal year.

Insider Activity at Insmed

In related news, insider Orlov Nicole Schaeffer sold 101,100 shares of Insmed stock in a transaction that occurred on Thursday, November 19th. The shares were sold at an average price of $145.26, for a total transaction of $14,685,786.00. Following the transaction, the insider owned 41,895 shares of the company’s stock, valued at $6,085,667.70. This trade represents a 70.70% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David Brennan sold 25,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 9th. The shares were sold at an average price of $124.00, for a total transaction of $3,100,000.00. Following the transaction, the director owned 39,238 shares of the company’s stock, valued at approximately $4,865,512. This represents a 38.92% decrease in their position. The SEC filing for this sale provides additional information. 2.10% of the stock is owned by company insiders.

Hedge Funds Weigh In On Insmed

Hedge funds and other institutional investors have recently made changes to their positions in the company. Pictet Asset Management Holding SA increased its position in shares of Insmed by 44.0% in the 3rd quarter. Pictet Asset Management Holding SA now owns 1,757,541 shares of the biopharmaceutical company’s stock valued at $200,845,000 after buying an additional 537,188 shares in the last quarter. Bellevue Group AG raised its stake in Insmed by 8.2% during the 3rd quarter. Bellevue Group AG now owns 1,508,034 shares of the biopharmaceutical company’s stock worth $172,127,000 after buying an additional 114,616 shares during the period. NWI Management LP lifted its holdings in Insmed by 2.6% during the first quarter. NWI Management LP now owns 1,014,000 shares of the biopharmaceutical company’s stock worth $165,809,000 after acquiring an additional 25,540 shares in the last quarter. Assenagon Asset Management S.A. lifted its holdings in Insmed by 480.4% during the third quarter. Assenagon Asset Management S.A. now owns 1,266,788 shares of the biopharmaceutical company’s stock worth $144,591,000 after acquiring an additional 1,048,518 shares in the last quarter. Finally, Bank of New York Mellon Corp bought a new position in Insmed during the second quarter worth about $139,966,000.

About Insmed

(Get Free Report)

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing treatments for serious diseases, including respiratory and rare conditions. The company is based in Bridgewater, New Jersey, and is led by President and Chief Executive Officer William H. Lewis Jr. Its commercial products include ARIKAYCE, an inhaled amikacin treatment for certain adults with refractory Mycobacterium avium complex lung disease, and BRINSUPRI (brensocatib), an oral treatment for non-cystic fibrosis bronchiectasis.

Further Reading

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.